Literature DB >> 16217711

Atypical MRI findings in Canavan disease: a patient with a mild course.

C Yalcinkaya1, G Benbir, G S Salomons, E Karaarslan, M O Rolland, C Jakobs, M S van der Knaap.   

Abstract

Canavan disease is a severe, progressive leukodystrophy with an autosomal recessive inheritance, caused by aspartoacylase (ASPA) deficiency. The characteristic MRI features include diffuse, symmetrical white matter degeneration in the subcortical areas, with bilateral involvement of the globus pallidus. Proton magnetic resonance spectroscopy of the brain shows an increase in the concentration of N-acetylaspartic acid (NAA). The altered NAA metabolism has been traced to mutations in the gene encoding ASPA, located on chromosome 17 (17p13-ter). We present here a patient with a mild form of Canavan disease confirmed with the absent ASPA activity, atypical MRI findings, related to compound heterozygosity for a missense mutation, p.Tyr288Cys, and the known pan-European mutation, the p.Ala305Glu.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217711     DOI: 10.1055/s-2005-872878

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  9 in total

1.  Magnetic resonance imaging findings of two sisters with Van der Knaap leukoencephalopathy.

Authors:  Koray Koç; Pınar Koç; Kamil Karaali; Nihal Olgaç Dündar; Utku Şenol; Arzu Canan
Journal:  Neuroradiol J       Date:  2015-10-01

2.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

3.  A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family.

Authors:  Rashida Hussain; Shakeela Daud; Naseebullah Kakar; Adeel Ahmad; Abdul Hameed Baloch; Abdul Malik Tareen; Muhammad Azam Kakar; Jamil Ahmad
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

Review 4.  Bilateral symmetrical basal ganglia and thalamic lesions in children: an update (2015).

Authors:  Giulio Zuccoli; Michael Paul Yannes; Raffaele Nardone; Ariel Bailey; Amy Goldstein
Journal:  Neuroradiology       Date:  2015-07-31       Impact factor: 2.804

5.  RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

Authors:  Michelle L Wynn; Joel A Yates; Charles R Evans; Lauren D Van Wassenhove; Zhi Fen Wu; Sydney Bridges; Liwei Bao; Chelsea Fournier; Sepideh Ashrafzadeh; Matthew J Merrins; Leslie S Satin; Santiago Schnell; Charles F Burant; Sofia D Merajver
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

6.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

7.  Atypical clinical and radiological course of a patient with Canavan disease.

Authors:  Catherine Sarret; Odile Boespflug-Tanguy; Diana Rodriguez
Journal:  Metab Brain Dis       Date:  2015-11-19       Impact factor: 3.584

8.  A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination.

Authors:  Marina R Carpinelli; Anne K Voss; Michael G Manning; Ashwyn A Perera; Anne A Cooray; Benjamin T Kile; Rachel A Burt
Journal:  Dis Model Mech       Date:  2014-03-28       Impact factor: 5.758

9.  Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.

Authors:  Marisa I Mendes; Desirée Ec Smith; Ana Pop; Pascal Lennertz; Matilde R Fernandez Ojeda; Warsha A Kanhai; Silvy Jm van Dooren; Yair Anikster; Ivo Barić; Caroline Boelen; Jaime Campistol; Lonneke de Boer; Ariana Kariminejad; Hulya Kayserili; Agathe Roubertie; Krijn T Verbruggen; Christine Vianey-Saban; Monique Williams; Gajja S Salomons
Journal:  Hum Mutat       Date:  2017-02-14       Impact factor: 4.878

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.